Peptide receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogs to disrupt tumor signaling, while Pembrolizumab blocks the interaction between PD-1 and PD-L1, enhancing the immune system’s ability to recognize and destroy tumor cells. The gene discussed is CD274; the disease is neoplasm.